Take­da hands TiGenix a rare, $434M mar­ket­ing deal for PhI­II stem cell ther­a­py

Bel­gian biotech TiGenix trig­gered a rare round of en­thu­si­asm for stem cell re­search a cou­ple of years back with news its lead off-the-shelf ther­a­py hit the pri­ma­ry end­point in a Phase III study treat­ing fis­tu­las in Crohn’s dis­ease pa­tients.  They backed it up a year lat­er with even more pos­i­tive da­ta. And now, a few months af­ter it was filed for ap­proval, Take­da is buy­ing its way in with a small deal to ac­quire the Eu­ro­pean rights to Cx601.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.